MINIMAL DISSEMINATED AND MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADOLESCENT NON‐HODGKIN LYMPHOMA

Introduction: Minimal disease determination might serve for risk stratification, response evaluation and follow-up monitoring in childhood Non-Hodgkin lymphomas. Besides helping to judge minimal residual (MRD) during therapy, detection of disseminated (MDD) at diagnosis may be prognostic value itself. However, different subtypes, high cure rates, low patient numbers, limited initial tumour material early progression pose challenges. Methods: Pubmed literature search on MDD MRD pediatric Results: Current clinical applications differ between the subtypes. For lymphoblastic lymphomas, both flow-cytometry detecting aberrant immunophenotypes PCR-based assays TCR- or Ig-rearrangements have been used measurement. A could not clearly established yet. has analysed larger cohorts so far. In Burkitt-lymphoma -leukemia, MYC-Ig-fusion sequences enable detection. While conflicting data role as factor Burkitt lymphoma published, leukaemia treated by risk-adapted chemotherapy described two study groups. its rituximab-era needs confirmed. ALK-positive anaplastic large cell (ALCL), determined qualitative quantitative PCR ALK-fusion transcripts are validated independent parameters. They standard care parameters assessed routine clinically practice stratification studies. Early even endpoint trials guiding individual therapy. Conclusions future outlook: Validation is required all subtypes but ALCL. Next-generation sequencing based methods use circulating cell-free DNA medium provide new options Keywords: diagnostic biomarkers, disease, non-Hodgkin (pediatric, adolescent, young adult) No conflicts interests pertinent abstract.